Literature DB >> 20403373

Detailed analysis of food-reinforced operant lever pressing distinguishes effects of a cannabinoid CB1 inverse agonist and dopamine D1 and D2 antagonists.

P J McLaughlin1, K M Winston, L A Swezey, V K Vemuri, A Makriyannis, J D Salamone.   

Abstract

Overt similarities exist between the effects of systemic cannabinoid CB1 inverse agonists and dopamine (DA) antagonists on appetitive behavior. The present set of studies was undertaken to apply a fine-grained analysis of food-reinforced operant lever pressing in rats in order to compare the pattern of effects produced by administration of the CB1 inverse agonist AM 251 and those induced by the DA D1 antagonist SKF 83566, and the D2 antagonist raclopride. Three groups of rats were trained on a fixed-ratio 5 (FR5) schedule and administered these compounds over a range of doses expected to suppress responding. All three drugs produced a dose-related suppression of total lever pressing. In addition to main effects of dose, regression analyses were performed to determine which of several response timing- and rate-related variables correlated most strongly with overall responding in each group. It was found that total session time spent pausing from responding was significantly better at predicting responding in the AM 251 group, while both DA antagonists produced significantly stronger regression coefficients (versus AM 251) from fast responding measures. These results suggest that, while several similarities exist, CB1, D1, and D2 antagonists are not identical in their pattern of suppression of food-maintained lever pressing. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20403373      PMCID: PMC5426058          DOI: 10.1016/j.pbb.2010.04.009

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  50 in total

1.  Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.

Authors:  Peter J McLaughlin; Liu Qian; JodiAnne T Wood; Ania Wisniecki; Keisha M Winston; Lynn A Swezey; Keita Ishiwari; Adrienne J Betz; Lakshmipathi Pandarinathan; Wei Xu; Alexandros Makriyannis; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2006-03-06       Impact factor: 3.533

2.  Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation.

Authors:  Amy J Tallett; John E Blundell; John R Rodgers
Journal:  Behav Pharmacol       Date:  2007-11       Impact factor: 2.293

3.  Haloperidol, raclopride, and eticlopride induce microcatalepsy during operant performance in rats, but clozapine and SCH 23390 do not.

Authors:  S C Fowler; J R Liou
Journal:  Psychopharmacology (Berl)       Date:  1998-11       Impact factor: 4.530

4.  Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism.

Authors:  G Tanda; F E Pontieri; G Di Chiara
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  Different behavioral effects of haloperidol, clozapine and thioridazine in a concurrent lever pressing and feeding procedure.

Authors:  J D Salamone; M S Cousins; C Maio; M Champion; T Turski; J Kovach
Journal:  Psychopharmacology (Berl)       Date:  1996-05       Impact factor: 4.530

6.  Haloperidol and nucleus accumbens dopamine depletion suppress lever pressing for food but increase free food consumption in a novel food choice procedure.

Authors:  J D Salamone; R E Steinpreis; L D McCullough; P Smith; D Grebel; K Mahan
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Ventrolateral striatal dopamine depletions impair feeding and food handling in rats.

Authors:  J D Salamone; K Mahan; S Rogers
Journal:  Pharmacol Biochem Behav       Date:  1993-03       Impact factor: 3.533

8.  Involvement of dopamine and opioids in the motivation to eat: influence of palatability, homeostatic state, and behavioral paradigms.

Authors:  M Flavia Barbano; Maryvonne Le Saux; Martine Cador
Journal:  Psychopharmacology (Berl)       Date:  2008-11-18       Impact factor: 4.530

9.  Cannabinoid pharmacological properties common to other centrally acting drugs.

Authors:  Jenny L Wiley; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2003-06-27       Impact factor: 4.432

10.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

View more
  4 in total

1.  Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

Authors:  Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

2.  Behavioral effects of the novel potent cannabinoid CB1 agonist AM 4054.

Authors:  Peter J McLaughlin; Ganesh A Thakur; V Kiran Vemuri; Evan D McClure; Cara M Brown; Keisha M Winston; Jodianne T Wood; Alexandros Makriyannis; John D Salamone
Journal:  Pharmacol Biochem Behav       Date:  2013-04-19       Impact factor: 3.533

3.  CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in rats.

Authors:  Emily E Thompson; Julia E Jagielo-Miller; V Kiran Vemuri; Alexandros Makriyannis; Peter J McLaughlin
Journal:  J Psychopharmacol       Date:  2016-03-22       Impact factor: 4.153

4.  CB1 Activity Drives the Selection of Navigational Strategies: A Behavioral and c-Fos Immunoreactivity Study.

Authors:  Daniela Laricchiuta; Francesca Balsamo; Carlo Fabrizio; Anna Panuccio; Andrea Termine; Laura Petrosini
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.